CAJ | 학술논문

目的观察肝康Ⅱ号降低慢性乙型肝炎(chronic hepatitis B)患者胆红素的疗效,并探讨其机理.方法 124例慢性乙型肝炎高胆红素血症患者,按数字法随机分为两组各62例,在常规治疗基础上,治疗组加肝康Ⅱ号治疗,对照组加茵栀黄颗粒治疗.观察治疗前后两组总胆红素(TBiL)、丙氨酸转氨酶(ALT)、门冬氨酸转氨酶(AST)、γ谷氨酰转肽酶(GGT)变化.对比分析治疗组、对照组治愈率、好转率.结果 ①治愈率、好转率:治疗组治愈50例(治愈率80.6％),好转12例(好转率19.4％);对照组治愈39例(治愈率62.9％),好转23例(好转率37.1％);治疗组治愈率高于对照组(x2=4.82,P＜0.05).②TBiL、ALT、AST、GGT变化:治疗前两组TBiL、ALT、AST、GGT比较,差异无统计学意义(P＞0.05);治疗后治疗组TBiL (20.75±3.77) μmol/L、ALT(52.53±12.23)U/L、AST (51.75±9.93) μmol/L、GGT (48.75±16.68) U/L明显低于对照组TBiL (26.68±4.99) μmmol/L、ALT (79.68±11.92) U/L、AST(60.12±8.12) μmol/L、GGT (58.97±15.47) U/L,差异均有统计学意义(P＜0.05～0.01).结论肝康Ⅱ号降低慢性乙型肝炎患者胆红素水平疗效确切.
목적 관찰간강Ⅱ호강저만성을형간염(chronic hepatitis B)환자담홍소적료효,병탐토기궤리.방법 124례만성을형간염고담홍소혈증환자,안수자법수궤분위량조각62례,재상규치료기출상,치료조가간강Ⅱ호치료,대조조가인치황과립치료.관찰치료전후량조총담홍소(TBiL)、병안산전안매(ALT)、문동안산전안매(AST)、γ곡안선전태매(GGT)변화.대비분석치료조、대조조치유솔、호전솔.결과 ①치유솔、호전솔:치료조치유50례(치유솔80.6％),호전12례(호전솔19.4％);대조조치유39례(치유솔62.9％),호전23례(호전솔37.1％);치료조치유솔고우대조조(x2=4.82,P＜0.05).②TBiL、ALT、AST、GGT변화:치료전량조TBiL、ALT、AST、GGT비교,차이무통계학의의(P＞0.05);치료후치료조TBiL (20.75±3.77) μmol/L、ALT(52.53±12.23)U/L、AST (51.75±9.93) μmol/L、GGT (48.75±16.68) U/L명현저우대조조TBiL (26.68±4.99) μmmol/L、ALT (79.68±11.92) U/L、AST(60.12±8.12) μmol/L、GGT (58.97±15.47) U/L,차이균유통계학의의(P＜0.05～0.01).결론 간강Ⅱ호강저만성을형간염환자담홍소수평료효학절.
Objective To observe the effect of Gankang Ⅱ in reducing bilirubin level of patients with chronic hepatitis B,and discuss the mechanism.Methods 124 cases hyperbilirubinemia patients with chronic hepatitis B were randomly divided into Gankang Ⅱ treatment group (the treatment group for short),and Yinzhihuang particles treatment group (the control group for short),with 62 eases in each group.The cure rate,recover rate of the treatment group and control group were observed,together with the changes of ALT,AST,GGT,and TBiL.Results ①The cure rate was 80.6％,the recover rate was 19.4％ in the treatment group; the cure rate of was 62.9％ and the recover rate was 37.1％ in the control group; the cure rate of the treatment group was obviously higher than the control group.② There was no significant difference between the treatment group and the control group on TBiL,ALT,AST,and GGT before the treatment (P＞0.05).while after treated,TBiL (20.75±3.77) μmol/L,ALT (52.53± 12.23) U/L,AST (51.75 ±9.93) μmol/L,GGT (48.75 ±16.68) U/L of the treatment group were obviously lower than the TBiL(26.68 ±4.99)μmol/L,ALT(79.68± 1 1.92)U/L,AST (60.12 ± 8.12) μmol/L,GGT (58.97±15.47)U/L of control group.There was significant difference(P＜0.05～0.01).Conclusion The effect of Gankang Ⅱ in reducing the bilirubin level of patients with chronic hepatitis B was sound.